Increasingly, biopharmaceutical companies are entering into risk-based payment arrangements with payers for medicines. Under these arrangements, payers often pay a variable rate depending on how well a medicine works for the intended patient. For patients, these arrangements can offer important benefits -- medicines that work best for them and, often, reduced patient costs.